ExpreS2ion announces successful manufacturing of the cVLP COVID-19 vaccine and further positive updates

Hørsholm, Denmark, November 16, 2020 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus like particle (cVLP) based COVID-19 vaccine, which is licensed to Bavarian Nordic, has been successfully manufactured with a full batch release to follow after final quality analysis. The project remains on track for presenting initial clinical Phase I/IIa results in Q1 2021, depending on the speed of the clinical trial application (CTA) approval procedure. Furthermore, the cVLP technology and manufacturing processes used are perfectly